The Expert Committee recommended the addition of the fixed-dose combination of glecaprevir + pibrentasvir to the core list of the EMLc for the treatment of children aged 3 to 12 years with chronic HCV infection, based on evidence of pan-genotypic effectiveness and an acceptable safety profile. The Committee noted that the results from the DORA trial demonstrated high rates of virological response in children and adolescents, comparable with those observed in adults. The Committee therefore also recommended that listing of glecaprevir + pibrentasvir on the EML be extended to include adolescents. The Committee also noted the planned inclusion of glecaprevir + pibrentasvir as one of the recommended regimens for children in the updated WHO Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection, and the licensing agreements in place between the manufacturer and the Medicines Patent Pool, which aims to facilitate affordable access to glecaprevir + pibrentasvir in low- and middle-income countries.